Literature DB >> 1721459

FK 506 in the management of transplant-related nephrotic syndrome and steroid-resistant nephrotic syndrome.

J McCauley1, R Shapiro, V Scantlebury, N Gilboa, M Jordan, C Jensen, A Naik, A Tzakis, D Ellis, T E Starzl.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1721459      PMCID： PMC3016871     

Source DB:  PubMed          Journal:  Transplant Proc        ISSN： 0041-1345            Impact factor:   1.066


× No keyword cloud information.
  6 in total

1.  Conversion from cyclosporine to FK 506 in liver allograft recipients with cyclosporine-related complications.

Authors:  J J Fung; S Todo; A Jain; J McCauley; M Alessiani; C Scotti; T E Starzl
Journal:  Transplant Proc       Date:  1990-02       Impact factor: 1.066

2.  FK 506 in steroid-resistant focal sclerosing glomerulonephritis of childhood.

Authors:  J McCauley; A G Tzakis; J J Fung; S Todo; T E Starzl
Journal:  Lancet       Date:  1990-03-17       Impact factor: 79.321

Review 3.  Selected topics on FK 506, with special references to rescue of extrahepatic whole organ grafts, transplantation of "forbidden organs," side effects, mechanisms, and practical pharmacokinetics.

Authors:  T E Starzl; K Abu-Elmagd; A Tzakis; J J Fung; K A Porter; S Todo
Journal:  Transplant Proc       Date:  1991-02       Impact factor: 1.066

4.  The recurrence of focal segmental glomerulosclerosis in kidney transplant patients treated with cyclosporine.

Authors:  G Banfi; C Colturi; G Montagnino; C Ponticelli
Journal:  Transplantation       Date:  1990-10       Impact factor: 4.939

5.  FK 506 for liver, kidney, and pancreas transplantation.

Authors:  T E Starzl; S Todo; J Fung; A J Demetris; R Venkataramman; A Jain
Journal:  Lancet       Date:  1989-10-28       Impact factor: 79.321

Review 6.  Ciclosporin in minimal-change glomerulopathy and in focal segmental glomerular sclerosis.

Authors:  C Ponticelli; E Rivolta
Journal:  Am J Nephrol       Date:  1990       Impact factor: 3.754
  6 in total
  8 in total

Review 1.  FK 506 and autoimmune disease: perspective and prospects.

Authors:  A W Thomson; T E Starzl
Journal:  Autoimmunity       Date:  1992       Impact factor: 2.815

Review 2.  FK 506: a novel immunosuppressant for treatment of autoimmune disease. Rationale and preliminary clinical experience at the University of Pittsburgh.

Authors:  A W Thomson; P B Carroll; J McCauley; J Woo; K Abu-Elmagd; T E Starzl; D H Van Thiel
Journal:  Springer Semin Immunopathol       Date:  1993

3.  FK 506 in the management of nephrotic syndrome after renal transplantation.

Authors:  J McCauley; R Shapiro; M Jordan; V Scantlebury; C Vivas; C Jensen; T E Starzl
Journal:  Transplant Proc       Date:  1993-02       Impact factor: 1.066

4.  Two-year experience with FK 506 in pediatric patients.

Authors:  A G Tzakis; J Reyes; S Todo; B Nour; R Shapiro; M Jordan; J McCauley; J Armitage; J J Fung; T E Starzl
Journal:  Transplant Proc       Date:  1993-02       Impact factor: 1.066

5.  Steroid-resistant nephrotic syndrome: long-term evolution after sequential therapy.

Authors:  Antonia Peña; Juan Bravo; Marta Melgosa; Carlota Fernandez; Carmen Meseguer; Laura Espinosa; Angel Alonso; M Luz Picazo; Mercedes Navarro
Journal:  Pediatr Nephrol       Date:  2007-09-18       Impact factor: 3.714

6.  Recurrent nephrotic syndrome after transplantation: early treatment with plasmaphaeresis and cyclophosphamide.

Authors:  P Cochat; A Kassir; S Colon; C Glastre; B Tourniaire; B Parchoux; X Martin; L David
Journal:  Pediatr Nephrol       Date:  1993-02       Impact factor: 3.714

Review 7.  Acute myocardial infarction in a young boy with nephrotic syndrome: a case report and review of the literature.

Authors:  L Hopp; N Gilboa; G Kurland; N Weichler; T J Orchard
Journal:  Pediatr Nephrol       Date:  1994-06       Impact factor: 3.714

8.  FK506 reduces albuminuria through improving podocyte nephrin and podocin expression in diabetic rats.

Authors:  X-M Qi; J Wang; X-X Xu; Y-Y Li; Y-G Wu
Journal:  Inflamm Res       Date:  2015-11-13       Impact factor: 4.575
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.